Literature DB >> 23338672

Fractionated stereotactic radiotherapy using Novalis for confined intra-orbital optic nerve glioma in pediatric patient.

Seong Rok Han1, Keung Nyun Kim, Gi-Taek Yee, Chan Young Choi, Dong Joon Lee, Moon Jun Sohn, Chae Heuck Lee.   

Abstract

INTRODUCTION: Optic gliomas are the most common tumors in the optic pathways during childhood. Among them, about 10 % are located within intra-orbital cavity. However, the optimal management for intra-orbital optic nerve gliomas remains controversial. An 11-year-old male complained about progressive decline of vision in his right eye. Brain MRI revealed a fusiform enlargement of right optic nerve within intra-orbital cavity.
MATERIALS AND METHODS: A presumptive diagnosis of optic nerve glioma was made. Therefore, we performed fractionated stereotactic radiotherapy (FSRT) using Novalis. DISCUSSION: Five years after FSRT treatment, follow-up MRI revealed size reduction of tumor and visual acuity improvement without radiation-related complications.

Entities:  

Mesh:

Year:  2013        PMID: 23338672     DOI: 10.1007/s00381-013-2031-x

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  15 in total

Review 1.  Diagnosis and management of optic nerve glioma.

Authors:  J Shapey; H V Danesh-Meyer; A H Kaye
Journal:  J Clin Neurosci       Date:  2011-11-08       Impact factor: 1.961

Review 2.  Spontaneous regression of optic pathways gliomas in three patients with neurofibromatosis type I and critical review of the literature.

Authors:  Manolo Piccirilli; Jacopo Lenzi; Catia Delfinis; Guido Trasimeni; Maurizio Salvati; Antonino Raco
Journal:  Childs Nerv Syst       Date:  2006-04-26       Impact factor: 1.475

3.  Visual changes after gamma knife surgery for optic nerve tumors. Report of three cases.

Authors:  Yang Kwon; Jun Seok Bae; Jae Myung Kim; Do Hee Lee; Soon Young Kim; Jae Sung Ahn; Jeong Hoon Kim; Chang Jin Kim; Byung Duk Kwun; Jung Kyo Lee
Journal:  J Neurosurg       Date:  2005-01       Impact factor: 5.115

4.  Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome.

Authors:  Stephanie E Combs; Daniela Schulz-Ertner; Dimos Moschos; Christoph Thilmann; Peter E Huber; Jürgen Debus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

Review 5.  Retinoblastoma--comparative analysis of external radiotherapy techniques, including an IMRT technique.

Authors:  Márcio Lemberg Reisner; Célia Maria Pais Viégas; Rachele Zanchet Grazziotin; Delano Valdivino Santos Batista; Túlio Meneses Carneiro; Carlos Manoel Mendonça de Araújo; Edson Marchiori
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-01       Impact factor: 7.038

6.  Fractionated stereotactic radiotherapy (FSRT) for optic glioma.

Authors:  J Debus; K O Kocagoncu; A Hoss; F Wenz; M Wannenmacher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-05-01       Impact factor: 7.038

7.  Neovascular glaucoma following stereotactic radiosurgery for an optic nerve glioma: a case report.

Authors:  Sohee Jeon; Na Young Lee; Chan Kee Park
Journal:  Korean J Ophthalmol       Date:  2010-08-03

8.  Severe dry-eye syndrome following external beam irradiation.

Authors:  J T Parsons; F J Bova; C R Fitzgerald; W M Mendenhall; R R Million
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-11-15       Impact factor: 7.038

9.  Natural history and clinical management of optic pathway glioma.

Authors:  J Astrup
Journal:  Br J Neurosurg       Date:  2003-08       Impact factor: 1.596

10.  Novalis radiosurgery of optic gliomas in children: preliminary report.

Authors:  Seong Rok Han; Sang Won Yoon; Gi Taek Yee; Chan Young Choi; Moon Jun Sohn; Dong Joon Lee; Choong Jin Whang
Journal:  Pediatr Neurosurg       Date:  2007       Impact factor: 1.162

View more
  1 in total

1.  Treatment options for optic pathway gliomas.

Authors:  Reena P Thomas; Iris C Gibbs; Linda Wei Xu; Lawrence Recht
Journal:  Curr Treat Options Neurol       Date:  2015-02       Impact factor: 3.598

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.